Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04797286 · ClinicalTrials.gov registry record · Phase 2
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
A Phase 2 study of Scleroderma and Mildly Elevated Pulmonary Pressures, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT04797286: Recruiting Phase 2 study of Scleroderma and Mildly Elevated Pulmonary Pressures, sponsored by Johns Hopkins University.
NCT04797286 is a Phase 2 study of Scleroderma and Mildly Elevated Pulmonary Pressures that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 30 participants, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04797286, a Phase 2 study of Scleroderma and Mildly Elevated Pulmonary Pressures, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.
Primary Outcome
As assessed by change in 6 minute walk distance (6MWD) in feet (from baseline to 4 months) between the sildenafil group and the placebo group.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sildenafil
Study Locations (2)
Louisiana
- Louisiana State University - New Orleans
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 2 |
What NCT04797286 shows while recruiting
NCT04797286 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Scleroderma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04797286 reports a single indexed study location in Louisiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT04797286 about?
NCT04797286 is a clinical study titled "Sildenafil for Early Pulmonary Vascular Disease in Scleroderma". This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.
What is the current status of trial NCT04797286?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-09-20. Estimated completion is 2026-09-01.
What conditions does trial NCT04797286 study?
This clinical trial studies the following conditions: Scleroderma, Mildly Elevated Pulmonary Pressures.
What interventions are being tested in trial NCT04797286?
The interventions under investigation include: Placebo (OTHER), Sildenafil (DRUG).
Who is sponsoring clinical trial NCT04797286?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04797286 being conducted?
This trial has 2 study locations across Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04797286's enrollment target sits among peer trials
30 18th of 23 higher than 6 of 23 other Scleroderma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Scleroderma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
-
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
RECRUITING · Phase 2
-
Psychological Treatments for Scleroderma
COMPLETED · Phase 2
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI